Effects of therapy with systemic glucocorticosteroids on endothelial function and hemostasis in patients with infective exacerbation of chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2012-0-2-40-45
Abstract
Summary. Changes in basic parameters of vascular endothelial function and thrombinaemia were analyzed in 111 patients with acute infective exacerbation of COPD upon therapy with systemic steroids. In acute infective exacerbation of COPD, increased levels of endotelin-1 and homocysteine as endothelial dysfunction markers, substantial increase in plasma D-dimer level and changes in thrombocyte aggregation were found. Treatment with systemic steroids led to decreasing in endotelium-1 and D-dimer levels which directly related to C-reactive protein. In stable COPD, high D-dimer level persisted that was considered as thrombogenic and thromboembolic risks in COPD patients with cardiovascular comorbidity.
About the Authors
I. Ya. TseimakhRussian Federation
A. P. Momot
Russian Federation
G. I. Kostyuchenko
Russian Federation
Yu. A. Filonova
Russian Federation
T. A. Kornilova
Russian Federation
I. P. Kramar
Russian Federation
A. G. Chuchalin
Russian Federation
References
1. Шмелев Е.И. Хроническая обструктивная болезнь легких. В кн.: Чучалин А.Г. (ред.). Респираторная медицина: Руководство. М.: ГЭОТАР-Медиа; 2007; т. 2: 597–651.
2. Maio S., Baldacci S., Carrozzi L. et al. The global burden of chronic respiratory diseases. Eur. Respir. Rev. 2006; 3: 21–29.
3. Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Часть I. ХОБЛ и поражения сердечно-сосудистой системы. Рус. мед. журн. 2008; 2: 58–65.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2009. www.goldcopd.org
5. Anthonisen N.R., Connett J.E., Enright P.L. et al. Hospitalization and mortality in the Lung Helth Study. Am. J. Respir. Crit. Care Med. 2002; 166: 333–339.
6. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165–1185.
7. Sin D.D., Man S.F. COPD as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorax Soc. 2005; 2 (1): 8–11.
8. MacNee W., Maclay J., McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc. Am. Thorax. Soc.; 2008; 5: 824–833.
9. Polosa R., Cacciola R.R., Prosperini G. et al. Endothelial – coagulative activation during chronic obstructive pulmonary disease exacerbations. Haematologica 2008; 93: 1275–1276.
10. Gunen H., Gulbas G., In E. et al. Venous thromboemboli and exacerbations of COPD. Eur. Respir. J. 2010; 35: 1243–1248.
11. Parrillo J.E., Dellinger R.P. Critical care medicine: principales of diagnosis and management in the adult. St. Louis: Mosby; 2002.
12. Wouters E.F., Groenewegen K.H., Dentener M.A. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc. Am. Thorac. Soc. 2007; 4 (8): 626–634.
13. Brotman D.J., Girod J.P., Garcia M.J. et al. Effects of short – term glucocorticoids on cardiovascular biomarkers. J. Clin. Endocrinol. 2005; 90: 3202–3208.
14. Кузник Б.И. Клеточные и молекулярные механизмы регуляции системы гемостаза в норме и патологии. Чита: Экспресс-издательство; 2010.
15. Мирошниченко И.И., Птицына С.Н., Кузнецова Н.Н. и др. Гомоцистеин – предиктор патологических изменений в организме человека. Рус. мед. журн. 2009; 4: 224–227.
Review
For citations:
Tseimakh I.Ya., Momot A.P., Kostyuchenko G.I., Filonova Yu.A., Kornilova T.A., Kramar I.P., Chuchalin A.G. Effects of therapy with systemic glucocorticosteroids on endothelial function and hemostasis in patients with infective exacerbation of chronic obstructive pulmonary disease. PULMONOLOGIYA. 2012;(2):40-45. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-2-40-45